Core Insights - Reckitt Benckiser is experiencing significant growth in emerging markets, particularly in China, which is expected to deliver double-digit growth in 2026 following a similar trend in 2025 [1][4][7] - The company's shift to a geography-led structure has contributed to this acceleration, allowing for dedicated leadership in emerging markets [3][4] - Europe is projected to remain a low-growth environment in 2026, with no clear catalysts for recovery [4][6] Emerging Markets Growth - China is highlighted as a major growth driver, benefiting from 20 years of investments, including local manufacturing and R&D facilities [2][7] - Reckitt's investments in live-streaming and e-commerce have significantly increased its market presence in China, with e-commerce now accounting for about 80% of its business there [8] - India is also expected to maintain steady high single-digit growth, supported by strong distribution and operational execution [9] Operating Model and Strategy - The transition to a geography-led structure has allowed Reckitt to prioritize emerging markets, which were previously overshadowed by developed markets [3][4] - The company is maintaining elevated capital expenditures (CapEx) at around 4% of revenue to support supply chain and manufacturing projects, rather than focusing on immediate gross-margin expansion [5][13] Market Performance - In Europe, category growth has deteriorated significantly, with projections indicating flat growth for 2026 [6][9] - North America is expected to show improvement in 2026, despite a challenging Q1 due to seasonal factors [11] Innovation and Product Development - Reckitt is investing approximately 2.9% of net revenue in R&D, with a focus on innovation to sustain top-line growth of 4%-5% [18][19] - New product launches, such as Lysol Air Sanitizer and Mucinex 12-hour cold and flu product, are part of the company's strategy to enhance its portfolio [19] Financial Outlook - The company aims to offset stranded costs from its Essential Home transaction through productivity programs, although it does not expect to fully offset these costs within 2026 [15] - Operating margins are projected to be around 24.9%, with a target to reduce fixed costs below 19% by the end of 2027 [15] Future Investments - Reckitt is planning significant investments in U.S. manufacturing capabilities, which will increase the share of products made in the U.S. to over 80% by 2027 [20] - The company is also exploring bolt-on M&A opportunities, particularly in the self-care sector, which is seen as under-penetrated in emerging markets [18]

Core Insights - The company reported strong financial performance in 2025, with growth driven by emerging markets and margin expansion supported by the Fuel for Growth program [4][5] - Core Reckitt's net revenue grew by 5.2% in 2025, surpassing the company's guidance of above 4% [3] - The company aims for 4%-5% growth in 2026, primarily led by emerging markets, while acknowledging challenges in Europe and seasonal OTC categories [5][16] Financial Performance - Adjusted operating profit increased by 5.3% at constant currency, with Core Reckitt's operating margin expanding by 90 basis points to 26.7% [1] - Group net revenue rose by 5%, with Mead Johnson Nutrition contributing 3.8% growth [3] - Free cash flow was £1.7 billion, with a conversion rate of 71% [6][7] Capital Returns and Leverage - The company returned £2.3 billion to shareholders, including £900 million in buybacks and a £1.6 billion special dividend [6][7] - Net debt to adjusted EBITDA ended the year at 1.6x, with expectations to peak near 2.5x by mid-2026 [8] - A 5% increase in the full-year dividend was proposed, aligning with the company's sustainable dividend growth strategy [9] Regional Performance - Emerging markets showed broad-based growth, with Core Reckitt growth of 14.6% and volumes up 6.7%, particularly in China and India [2][10] - Europe experienced a decline of 1.4% due to slowing category growth and increased promotional activity, although adjusted operating margin rose to 31.4% [11] - North America was broadly flat, with a 0.2% increase in like-for-like net revenue [12] Strategic Initiatives - The Fuel for Growth program is central to investment capacity and margin performance, with fixed costs improving to 19.4% of net revenue in 2025 [12] - Capital expenditure increased to £592 million, focusing on localization, automation, and digitization to enhance supply chain resilience [13] - Innovation remains a priority, with new product launches planned, including Mucinex 12 Hour Cold and Fever [14] Category Performance - Self-care net revenue increased by 3%, driven by high single-digit growth in non-seasonal self-care products [15] - Germ protection grew by 8.4%, led by strong performance from Dettol in emerging markets [15] - Intimate Wellness was the fastest-growing category, up 12.5% like-for-like, with significant growth in brands like Durex and Veet [15]

A SIMPLER, SHARPER RECKITT CAGNY 19th February 2026 CAUTIONARY NOTE CONCERNING FORWARD –LOOKING STATEMENTS This presentation and any other information discussed at the presentation (collectively, the "presentation") has been prepared by Reckitt Benckiser Group plc (the "Company") solely for your information. The opinions presented herein are based on general information gathered at the time of writing and are subject to change without notice. Information in this presentation sourced from third parties has b ...

Core Insights - Reckitt Benckiser Group plc has qualified to trade on the OTCQX® Best Market, upgrading from the Pink® market, which enhances its visibility and accessibility for U.S. investors [1][3][4] - The trading symbols for Reckitt on OTCQX are "RBGLY" and "RBGPF," with current financial disclosures available on the OTC Markets website [2] - The upgrade to OTCQX signifies Reckitt's commitment to transparency and adherence to high financial standards and corporate governance practices [3][4] Company Overview - Reckitt is known for its consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish, and Veet, focusing on innovative, science-backed solutions for healthier living [4][5] - The company's mission is to protect, heal, and nurture, aiming for a cleaner and healthier world while expanding access to healthcare and driving sustainable innovation [5][6] Industry Context - OTC Markets Group Inc. operates regulated markets for trading 12,000 U.S. and international securities, providing a platform for companies to access U.S. financial markets efficiently [7][8]